BioHistory Moment: Diamond v. Chakrabarty case argued before U.S. Supreme Court
On March 17, 1980, the Diamond v. Chakrabarty case was argued before the U.S. Supreme Court regarding the
patentability of genetically altered microorganisms.
In 1972, Chakrabarty filed a patent application assigned to the General Electric Co. for a human-made genetically
engineered bacterium capable of breaking down multiple components of crude oil. The application asserted 36 claims
related to Chakrabarty's invention of a bacterium from the genus Pseudomonas containing at least two
stable energy-generating plasmids, each of said plasmids providing a separate hydrocarbon degradative pathway.
On June 16, 1980, the U.S. Supreme Court upheld five-to-four the patentability of genetically altered organisms,
opening the door to greater patent protection for any modified life forms. Chief Justice Warren Burger
delivered the opinion of the Court, in which justices Potter Stewart, Harry Blackmun, William Rehnquist, and
John Paul Stevens joined. William Brennan filed the dissenting opinion, in which Byron White, Thurgood Marshall,
and Lewis Powell joined.
 More...
Learn about Seattle's Life Science Incubator Facility
Seattle's Life Science Incubator Research facility was commissioned in 1988, and is a contemporary-designed building provided with
modern research systems. Four floors are specifically laboratory space, one floor is a fully equipped vivarium and one floor is clinical
space and management offices. The faciility is centrally located in close proximity to downtown Seattle, the University of Washington,
the Fred Hutchinson Cancer Research Center, and more.
Learn about this and other biotechnology, medical device and pharmaceutical facilities available for sale,
lease or sublease in New York, regionally or nationwide.
More...
(Advertising)
|
|
|
Industry News...
Free News Release Posting & Archiving Service
- Abbott announces positive data from ABSORB trial Abbott announced positive 30-day results from patients enrolled in the second phase of the ABSORB trial. Patients treated with the bioresorbable vascular scaffold demonstrated no cases of blood clots, no repeat procedures and a low rate of major adverse cardiac events.
Abbott March 15, 2010
- New analysis assesses impact of common genetic variation of antiplatelet therapy An analysis of a TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients in the study were treated with dual antiplatelet therapy with either Plavix plus aspirin or Effient plus aspirin and managed with percutaneous coronary intervention.
Eli Lilly and Company March 15, 2010
- Portola Pharmaceuticals and Merck announce phase 2 study results Portola and Merck announced the results of EXPLORE-Xa, a Phase 2 exploratory dose finding study of betrixaban that showed a once-daily dose of oral betrixaban reduced the incidence of major and clinically relevant non-major bleeds compared to dose-adjusted warfarin.
Merck & Co., Inc. March 15, 2010
- Medtronic announces initial results of STOP AF clinical trial Medtronic announced data from a STOP AF clinical trial that showed superiority over anti-arrhythmic drugs, with 69.9 percent of patients with paroxysmal atrial fibrillation treated with the Arctic Front Cardiac CryoAblation Catheter System remaining free of atrial fibrillation one year later.
Medtronic, Inc. March 15, 2010
- Mayo Clinic study finds link between hypoglycemia and mortality rates in critically ill In a study published in the March issue of Mayo Clinic Proceedings, researchers report that they have found a link between mild to moderate hypoglycemia and mortality in critically ill patients. Mild to moderate degrees of hypoglycemia were previously considered clinically unimportant.
Mayo Clinic March 15, 2010
More... | Submit News Release | Advertising...
|
New Job Postings...
Free Job Posting Trial Offer
More... |
Job Advertising...
| About Job Postings...
|
New Facilities Available...
ATC clean room constructors...validation guaranteed!
More... |
Facility Advertising...
|
Upcoming Events...
 More... |
Submit Event |
Event Advertising...
|
|
Learn About New York's BioHistory
Why is there a life science industry in New York? Is the industry
growing? What do other states have?
Through New York BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industry in New York.
More...
BioEvolution Posters
More...
March - National Colorectal Cancer Awareness Month
As a leading health organization for 25 years, the Prevent Cancer Foundation, the vision of Carolyn Aldigé, has
catapulted cancer prevention to prominence and provided more than $113 million in support of cancer prevention
and early detection research, education and community outreach programs across the country.
More...
BioFact
(1923) - More than 50,000 foreign plants have been introduced into the United States since 1862 by the USDA. Along with these plants came 90% of the pests that plague agriculture today; most are invisible microbes.
It's a Small World
|
| |
Salmonella Typhimurium
| |
Science Quote
"Always do right. This will gratify some people and astonish the rest."
| - |
Mark Twain, American writer
|
|
(1835-1910)
|
|
